研讨参考主题：

1、全球公共安全形势、社会背景与应对策略；

2、现代社会的脆弱性与反脆弱行动；

3、灾害风险的预测与评估技术；

4、中国/美国应急管理体制及其运行机制设计；

5、区域灾害风险的预测与评估技术；

6、福建省/中国/美国应急管理产业发展重点领域与战略布局；

7、其他应急管理相关主题。

美国南加州大学（USC）教授简介

l Eric Heikkila教授/博士

南加州大学Price公共政策学院的终身教授并且负责学院的国际合作项目。他是经过培训的经济学家并且在三个领域发表了许多的研究：城市和区域发展、城市信息系统以及东亚城市和文化。他的著作《规划经济学》由Rutgers大学城市政策研究中心发表。作为城市发展环太平洋理事会的联合创立者和执行秘书， Heikkila教授专注于环太平洋地区城市发展的学者和专业人员间建立坚实的国际间联系。作为Fulbirght奖学金的获得者，他在北京大学城市和环境学院进行了为期一学年的中国城市化的联合研究。Eric Heikkila, Ph.D., is a tenured Professor at and Director of International Initiatives at the USC Price School. He is an economist by training and has been published extensively in three mains as of research: urban and regional development, urban information systems, and East Asian cities and cultures. His book, The Economics of Planning, was published by the Center for Urban Policy Research at Rutgers University. As co-founder and executive secretary of the Pacific Rim Council on Urban Development, Professor Heikkila has been instrumental in developing and maintaining a strong international network of scholars and practitioners who are involved in urban development throughout the Pacific region. As a recipient of a Fulbright Fellowship, he spent an academic year with Beijing University’s Department of Urban and Environmental Sciences, where he undertook joint research on urbanization in China.

l Najmedin (Najm) Meshkati教授/博士

南加州大学Viterbi工程学院土木/环境工程和工业及系统工程的教授。他是Jefferson科学研究员以及美国国务卿科学技术顾问办公室的科学和技术资深顾问（2009­2010）。Meshkati博士为众多国内和国际技术组织就航空（和其他四种运输模式）、石油化工以及核安全的设计、评估、人为因素和安全文化相关的议题提供咨询。在2007年他从人因工程学会（Human Factors and Ergonomics Society)获得了Oliver Keith Hansen推广奖，为他在“人为因素对于复杂、大型技术系统的影响和对于推广关于关键人为因素和其对人类带来的好处的公共认知所做出的贡献”，Meshkati博士是唯一的持续在人为因素和航空器安全领域（如：机舱设计、飞行员失误和侵入跑道等）进行研究的全职USC教授。他同时在USC国际知名的拥有60年历史的航空器安全项目教授了20年。他是国家工程院/国家研究委员会就评估英国石油公司深水平台爆炸、火灾和原油泄漏所成立的委员会的一员。这个委员会负责采取措施以防类似事件在未来发生。
Dr. Najmedin (Najm) Meshkati is Professor of Civil/Environmental Engineering and Industrial & Systems Engineering at the University of Southern California Viterbi School of Engineering. He was a Jefferson Science Fellow and Senior Science and Engineering Advisor, Office of Science and Technology Adviser to the Secretary of State (2009­2010). Dr. Meshkati has consulted for many domestic and international technological organizations on aviation (and other four modes of transportation), petrochemical, and nuclear safety; design, evaluation, human factors, and safety culture ­related matters. He is the 2007 recipient of the Oliver Keith Hansen Outreach Award from the Human Factors and Ergonomics Society (HFES) and was honored by the HFES for his “scholarly efforts on human factors of complex, large­ scale technological systems...[and] efforts to enhance public awareness of critical human factors issue [and] the benefits it brings to humankind.” Dr. Meshkati is the only full­time USC faculty member who has continuously been conducting research on human factors and aviation safety ­related issues (e.g., cockpit design, pilot error, and runway incursions) and teaching in the USC 60­year old internationally renowned Aviation Safety and Security Program, for the past twenty ­two years. He was also a member of the National Academy of Engineering/National Research Council’s Committee on the Analysis of Causes of the BP Deepwater Horizon Explosion.

l Michael B. Nichol教授/博士

Nichol博士期初是俄勒冈州卫生规划和发展署卫生规划师，1978-1984年成为策划总监，副总监，以及西俄勒冈卫生系统局的常务理事。在他担任执行董事期间，该机构开发了第一个医生具体收费指南，并公布给广大市民。此外，该机构主办的多个公共听证会使之成为俄勒冈州医疗补助计划卫生工作的重点。在负责医药经济与政策部期间，Nichol教授设立了医药经济与政策科学硕士，这已经成为该领域首屈一指的研究生学位之一。他曾在多项国家理事会和委员会工作，包括全国委员会的质量保证心血管工作组，国家质量论坛的国家自愿达成一致的治疗药物管理素质教育与坚持技术咨询小组，卫生保健研究和质量（AHRQ）医疗保健系统研究性学习机构。除了任现职卫生政策学教授，Nichol博士担任USC price公共政策学院的临时副院长，负责学院事务和指导学校的研究生医疗项目。这些项目包括法医疗管理硕士和医疗管理行政硕士。在过去的两年中， MHA和EMHA已经被重新调整，以期在学生的表现和职业素养方面有更突出的成果。尼科尔博士也是医药经济与政策的药学院教授以及Leonard D. Schaeffer中心卫生政策与经济学研究员。尼科尔教授积极从事相关项目研究，这些项目由联邦及企业资助。在医疗主题方面他已经出版了超过250同行评议的论文，他在许多制药和健康保险公司以及在加州各大医疗组织中担当顾问。

Dr. Nichol began his health care career as a health planner with the Oregon State Health Planning and Development Agency. He became planning director, associate director, and then executive director of the Western Oregon Health Systems Agency, between the years of 1978 and 1984. During his tenure as executive director, the Agency developed the first physician-specific fee guide, which was distributed to the general public. In addition, the Agency sponsored multiple public hearings as a part of the Oregon Health Decisions project, which resulted in a set of health priorities for the Oregon Medicaid program.While directing the Department of Pharmaceutical Economics and Policy, Professor Nichol developed the Master of Science in Pharmaceutical Economics and Policy, which has become one of the premier graduate degrees in the field. He has served on a number of national boards and committees, including the National Commission on Quality Assurance Cardiovascular Work Group, the National Quality Forum’s National Voluntary Consensus Standards for the Reporting of Therapeutic Drug Management Quality Education and Adherence Technical Advisory Panel, the Agency for Healthcare Research and Quality (AHRQ) Healthcare Systems Research Study Section, and a study section for the Patient Centered Outcomes and Research Institute (PCORI). Professor Nichol was President of the USC Faculty during the 2008-2009 academic year.In addition to his present appointment as Professor of Health Policy, Dr. Nichol serves as USC Price’s Interim Vice Dean for Faculty Affairs and directs the school’s Graduate Health Programs. These programs includes the Master in Health Administration and the Executive Master in Health Administration. In the last two years, both the MHA and the EMHA have been re-designed to create clear outcomes for student performance and career attainment. Dr. Nichol is also Professor of Pharmaceutical Economics and Policy in the School of Pharmacy, and a Research Fellow at the Leonard D. Schaeffer Center for Health Policy and Economics Professor Nichol maintains an active research program enabled by federal and corporate grants. He has published more than 250 peer-reviewed articles and abstracts on a variety of health topics. He regularly consults for pharmaceutical and health insurance companies, as well as large physician groups within California.